10-K · March 18, 2026
Hyperfine positions itself as the first-mover in AI-powered portable ultra‑low‑field (ULF) brain MRI with a commercial rollout of a next‑generation Swoop® scanner and Optive AI™ software in 2025 and an expanding patent…
Earnings analysis · 10-Q
HYPR earnings analysis
Filed May 12, 2026 · Our reading of the company's report
The latest report
Hyperfine, Inc. reported Q1 2026 revenue of $3.90 million, an 83% increase year-over-year, along with an EPS of -$0.09, matching consensus estimates. The company continues to face high cash burn but has improved its…
Read full summary
Hyperfine, Inc. reported Q1 2026 revenue of $3.90 million, an 83% increase year-over-year, along with an EPS of -$0.09, matching consensus estimates. The company continues to face high cash burn but has improved its gross margin significantly, indicating strong sales performance and operational adjustments. Management maintains full-year revenue guidance of $20 to $22 million, reflecting a solid growth outlook.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.09
- Gross margin
- 50.7%
- Segment
- Device
- Segment
- Service
What stood out
-
Revenue Up 83% YoY
Q1 2026 revenue reached $3.90 million, up from $2.13 million in Q1 2025.
-
Gross Margin Improvement
Gross profit for Q1 2026 improved to $1.98 million, a 124.1% increase compared to the prior year.
-
Reduction in Operating Loss
Loss from operations decreased to $8.56 million, down from $10.90 million YoY.
-
Increased Units Sold
Sales of Swoop® systems increased by 67% year-over-year to 10 units sold.
-
Cash Position Solidified
As of March 31, 2026, cash and cash equivalents were $40.8 million.
-
Continued Investment in R&D
R&D expenses decreased 23.7% to $3.85 million, signaling potential efficiency improvements in spending.
What to watch
-
High Cash Burn Persisting
Net loss for Q1 2026 stood at $8.62 million, reflecting ongoing cash usage.
-
Debt Repayment Obligations
The company entered into a $15 million term loan with interest, increasing financial obligations.
-
Operational Dependency on Innovation
Future revenue relies heavily on successful commercialization of the updated Swoop® system.
Management's outlook
Management reaffirmed full-year 2026 revenue guidance of $20 million to $22 million, indicating expected growth.
Earlier filings 4
10-K · March 17, 2025
Hyperfine positions the Swoop® portable ultra‑low‑field MRI as an AI‑powered, lower‑cost alternative to conventional MRI with an estimated U.S. TAM of "more than $16 billion" and an expanding installed base supported by…
10-K · March 22, 2024
Hyperfine positions itself as the first FDA-cleared portable ultra-low-field (ULF) brain MRI platform (Swoop®) targeting decentralized imaging with AI-powered reconstruction and an expanding install base. The company…
10-Q · November 9, 2023
Hyperfine reported Q3 2023 revenue of $2,330,000, essentially flat versus $2,348,000 in Q3 2022, with gross margin expanding to $1,124,000 (48.2% of revenue). Operating loss narrowed to $11,759,000 and net loss improved…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.